| Literature DB >> 18266966 |
M Thirunavukkarasu1, S Addya, B Juhasz, R Pant, L Zhan, S Surrey, G Maulik, V P Menon, N Maulik.
Abstract
This study addresses an important clinical issue by identifying potential candidates of vascular endothelial growth factor (VEGF) signalling through the Flk-1 receptor that trigger cardioprotective signals under ischaemic stress. Isolated working mouse hearts of both wild-type (WT) and Flk-1(+/-) were subjected to global ischaemia (I) for 30 min. followed by 2 hrs of reperfusion (R). Flk-1(+/-) myocardium displayed almost 50% reduction in Flk-1 mRNA as examined by quantitative real-time RT-PCR at the baseline level. Flk-1(+/-) mouse hearts displayed reduction in left ventricular functional recovery throughout reperfusion (dp/dt 605 versus 884), after 2 hrs (P<0.05). Coronary (1.9 versus 2.4 ml) and aortic flow (AF) (0.16 versus 1.2 ml) were reduced in Flk-1(+/-) after 2 hrs of reperfusion. In addition, increased infarct size (38.4%versus 28.41%, P<0.05) and apoptotic cardiomyocytes (495 versus 213) were observed in Flk-1(+/-) knockout (KO) mice. We also examined whether ischaemic preconditioning (PC), a novel method to induce cardioprotection against ischaemia reperfusion injury, through stimulating the VEGF signalling pathway might function in Flk-1(+/-) mice. We found that knocking down Flk-1 resulted in significant reduction in the cardioprotective effect by PC compared to WT. Affymetrix gene chip analysis demonstrated down-regulation of important genes after IR and preconditioning followed by ischaemia reperfusion in Flk-1(+/-) mice compared to WT. To get insight into the underlying molecular pathways involved in ischaemic PC, we determined the distinct and overlapping biological processes using Ingenuity pathway analysis tool. Independent evidence at the mRNA level supporting the Affymetrix results were validated using real-time RT-PCR for selected down-regulated genes, which are thought to play important roles in cardioprotection after ischaemic insult. In summary, our data indicated for the first time that ischaemic PC modifies genomic responses in heterozygous VEGFR-2/Flk-1 KO mice and abolishes its cardioprotective effect on ischaemic myocardium.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18266966 PMCID: PMC3865673 DOI: 10.1111/j.1582-4934.2008.00269.x
Source DB: PubMed Journal: J Cell Mol Med ISSN: 1582-1838 Impact factor: 5.310
Fig. 1RT-PCR and real-time RT-PCR analysis for Flk-1, Flt-1 and vascular endothelial growth factor (VEGF). (A) Relative abundance (%) of Flk-1, Flt-1 and VEGF mRNA in wild-type (WT) and Flk-1+/− knockout myocardium (n= 6/group) at the baseline level, after ischaemia/reperfusion (IR) and after ischaemic preconditioning (PCIR) followed by IR. (B) Quantitative real-time RT-PCR analysis validating RT-PCR data for VEGF, Flt-1 and Flk-1 mRNA. *P < 0.05 compared with WT ischaemia/reperfusion, #P < 0.05 compared with WT preconditioning, †P < 0.05 compared with KO ischaemia/reperfusion.
Fig. 2Effects of ischaemia/reperfusion and preconditioning on left ventricular function of wild-type and Flk-1+/− mice. Post-ischaemic ventricular recovery of Flk-1+/− and wild-type mouse hearts (n = 6/group) is presented. The results (A) left ventricular developed pressure (LVDP), (B) dp/dtmax and (C) aortic flow are shown in Mean ± S.D form six animals per group. *P < 0.05 compared with WT ischaemia/reperfusion, #P < 0.05 compared with WT preconditioning, †P < 0.05 compared with knockout (KO) ischaemia/reperfusion. WTIR, wild-type IR; WTPCIR, preconditioned wild-type, KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.
Fig. 3Effects of ischaemia/reperfusion and preconditioning on infarct size and cardiomyocyte apoptosis of wild-type and Flk-1+/− mice. (A) Infarct size of the hearts is expressed as a percentage of the area at risk in mouse myocardium subjected to 30 min. of ischaemia followed by 2 hrs of reperfusion. Results are expressed as means ± SD of six hearts/group. (B and C) TUNEL assay for apoptotic cardiomyocytes cells after ischaemia/reperfusion and preconditioning of wild-type and Flk-1+/− mice after ischaemia. TUNEL assay for apoptotic cells was performed as described under Experimental procedures. Representative photographs show immunohistochemical staining of extended DNA. Results are expressed as means ± SEM of six hearts/group. *P < 0.05 compared with wild-type ischaemia/reperfusion group, #P < 0.05 compared with Flk+/− ischaemia/reperfusion group, †P < 0.05 compared with wild-type preconditioning group. WTIR, wild-type IR; WTPCIR, preconditioned wild-type; KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.
Fig. 4Volcano plot pictures showing the differentially regulated genes in both the comparisions. (A) KOIR versus WTIR, (B) KOPCIR versus WTPCIR. Volcano plot was used as filter to view the differentially expressed genes. A volcano plot shows the log2(Fold change) in x-axis against the –log10(P-value) in y-axis. It shows two important measures of differential expression in one plot. Filter genes for a 1.5-fold difference and P-value cut-off of 0.1. WTIR, wild-type IR; WTPCIR, preconditioned wild-type; KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.
Differentially expressed genes in KOIR mice as compared with WTIR mice at different statistical criteria using Volcano plot as a filter
| Fold change | Probe sets | 100 Cut-off | Unique genes after 100 cut-off | |
|---|---|---|---|---|
| 2 | 0.05 | 79 | 18 | 18 |
| 2 | 0.1 | 172 | 34 | 32 |
| 1.5 | 005 | 306 | 56 | 56 |
| 1.5 | 0.1 | 628 | 115 | 114 |
Differentially expressed genes in KOPCIR mice as compared with WTPCIR mice at different statistical criteria using Volcano plot as a filter
| Fold change | Probe sets | 100 Cut-off | Unique genes after 100 cut-off | |
|---|---|---|---|---|
| 2 | 0.05 | 195 | 64 | 62 |
| 2 | 0.1 | 419 | 143 | 138 |
| 1.5 | 005 | 646 | 187 | 180 |
| 1.5 | 0.1 | 1394 | 448 | 425 |
Fig. 5Hierarchic clustering of differentially expressed genes in wild-type and FLK-1+/− mice after Ischaemia reperfusion and ischaemic preconditioning. Data filtering by volcano plot identified 555 genes together in both the comparisons (WTIR versus KOIR and WTPCIR versus KOPCIR). Gene expression levels are depicted as colour variation from red (high expression) to blue (low expression) The colour in each cell of the figure displays the level of expression for each gene (row) in the myocardium of each group (mean of duplicate valve) (column). WTIR, wild-type IR; WTPCIR, preconditioned wild-type; KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.
List of selected down-regulated genes in WTIR versus KOIR
| Affy ID | Gene symbol | Description |
|---|---|---|
| 1419697_at | CXCL11 | Chemokine (C-X-C motif) ligand 11 |
| 1437478_s_at | EFHD2 | EF hand domain containing 2 |
| 1423136_at | FGF1 | Fibroblast growth factor 1 |
| 1424877_a_at | ALAD | Aminolevulinate, δ-, dehydratase |
| 1434008_at | SCN4B | Sodium channel, type IV, β |
| 1417343_at | FXYD6 | FXYD domain-containing ion transport regulator 6 |
| 1448304_a_at | RAB6 | RAB6, member RAS oncogene family |
| 1449379_at | KDR | Kinase insert domain protein receptor |
| 1452445_at | SLC41A2 | Solute carrier family 41, member 2 |
| 1436576_at | A630077B13RIK | RIKEN cDNA A630077B13 gene |
| 1424365_at | 1810037I17RIK | RIKEN cDNA 1810037I17 gene |
| 1416124_at | CCND2 | Cyclin D2 (very important) |
| 1439540_at | MARCH2 | Membrane-associated ring finger (C3HC4) 2 |
| 1451343_at | VPS36 | Vacuolar protein sorting 36 |
| 1450036_at | SGK3 | Serum/glucocorticoid-regulated kinase 3 |
| 1436959_x_at | NELF | Nasal embryonic LHRH factor |
| 1452053_a_at | TMEM33 | Transmembrane protein 33 |
| 1459783_s_at | CNO | Cappuccino |
| 1434598_at | LARP5 | La ribonucleoprotein domain family, member 5 |
| 1448780_at | SLC12A2 | Solute carrier family 12, member 2 |
| 1422464_at | MRPL3 | Mitochondrial ribosomal protein L3 |
| 1415943_at | SDC1 | Syndecan 1 |
| 1434577_at | BC052040 | cDNA sequence BC052040 |
| 1422492_at | CPOX | Coproporphyrinogen oxidase |
List of selected Down-regulated genes in WTPCIR versus KOPCIR
| Affy ID | Gene symbol | Description |
|---|---|---|
| 1448183_a_at | Hifla | Hypoxia inducible factor 1, α subunit |
| 1416123_at | Ccnd2 | Cyclin D2 |
| 1449379_at | Kdr | Kinase insert domain protein receptor |
| 1437284_at | Fzd1 | Frizzled homologue 1 (Drosophila) |
| 1415988_at | Hdlbp | High-density lipoprotein (HDL) binding protein |
| 1433972_at | Camtal | Calmodulin-binding transcription activator 1 |
| 1420491_at | Eif2s1 | Eukaryotic translation initiation factor 2, subunit 1 α |
| 1455396_at | Atp8b1 | ATPase, class I, type 8B, member 1 (Atp8b1), mRNA |
| 1428230_at | Prkcn | Protein kinase C, μ |
| 1459457_at | Camk2d | Calcium/calmodulin-dependent protein kinase II, δ |
| 1425354_a_at | Aggfl | Angiogenic factor with G patch and FHA domains 1 |
| 1421821_at | Ldlr | Low-density lipoprotein receptor |
| 1423144_at | Pik3ca | Phosphatidylinositol 3-kinase, catalytic, alpha polypeptide |
| 1425512_at | Map2k7 | Mitogen-activated protein kinase kinase 7 |
| 1424681_a_at | Psma5 | proteasome (prosome, macropain) subunit, alpha type 5 |
| 1418453_a_at | Atp1b1 | ATPase, Na+/K+ transporting, beta 1 polypeptide |
| 1430500_s_at | Mtx2 | Metaxin 2 |
| 1451090_a_at | Eif2s3x | Eukaryotic translation initiation factor 2, subunit 3, structural gene X-linked |
| 1436003_at | Vcaml | Vascular cell adhesion molecule 1 |
| 1460303_at | Nr3c1 | Nuclear receptor subfamily 3, group C, member 1 |
| 1430990_s_at | Mrpl44 | Mitochondrial ribosomal protein L44 |
| 1425993_a_at | Hsp110 | Heat shock protein 110 |
| 1423330_at | Ensa | Endosulfine α |
| 1423456_at | Bzw2 | Basic leucine zipper and W2 domains 2 |
| 1417204_at | Kdelr2 | KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 |
| 1433641_at | Smad5 | MAD homologue 5 (Drosophila) |
Fig. 6A Venn diagram shows the common differentially expressed genes in between two comparisons, (KO I/R versus WT I/R and KOPCIR versus WT PCIR). (B). Pie chart shows the classification of differentially expressed genes based on biological functions (Netaffx gene ontology tool, Affymetrix). The number represents the genes associated with a specific function. Note that some genes may have multiple functions and be classified in several categories. WTIR, wild-type IR; WTP-CIR, preconditioned wild-type; KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.
Selected genetic networks with high scores (>10) in WTIR versus KOIR comparison
| Molecules in network | Score | Focus genes | Top functions |
|---|---|---|---|
| Akt, Ap1, BTRC, CAMK2D, CLEC11A, CXCL1, CXCL11 (includes EG:6373), EIF2S1, FCGR1A, FGF1, HIF1A, H0MER1, IL1, IL11, IL1R2, Jnk, MAP3K3, Mapk, Mek, P38 MAPK, PI3K, Pkc(s), PMCH, PP2A, PPP1R1A, PSCD3, PSCDBP, PSMC3IP, PTGFR, RTN4, SIAH1,SLC12A7, ULBP2, Vegf, WNK1 | 42 | 22 | Cardiovascular system development and function, cell-to-cell signalling and interaction, gene expression |
| Amino acids, ARHGDIG, ARHGEF11, B3GALT2, CASC3, CD38, CDC6, CDC25C, CENPJ, COG2, COG7, CPE, GYS1 (includes EG:2997), HNRPA1, HNRPC, hydrogen peroxide, INS1, MAGOH, MCF2L, MPO, NXF1, PHGDH, PLK3, P0LR2A, P0U2F1, PPM1D, PTPRO, RBM8A, RCN1, RHOA, RHPN2, SYTL4, THOC4, TNF, TNFAIP8 | 27 | 15 | Carbohydrate metabolism, lipid metabolism, molecular transport |
| ARFGEF1, ARHGDIG, ARHGEF11, β-estradiol, CAD, CD200, CD200R1, CDH4, CLCN3, CRSP2, CUBN, DOK1, EGF, FOXA2, HCRTR2, IGHMBP2, LDLR, Mmp, MMP2, MY09B, PDGFB, PKIB, PLCE1, PSCD3, RHOA, SCARB1, SERPINA1, SETD7, SGK3, SLC9A3R1, TAF7, TBN, TBP, TRFP, USP6NL | 25 | 15 | Lipid metabolism, molecular transport, small molecule biochemistry |
| AK3L1, ATR, CCNA1, CCNA2, CD9, CDC6, CDC25A, CDC25B, CDC25C, CDK6, CHEK2, COL18A1, CPOX, E2F6, E2F1 (includes EG:1869), EGLN1, ERCC3, FBXW11, FLU, GTF2H1, HIF1A, MGA (includes EG:23269), MXD4, MYCT1, NDNL2, NRN1, PRKDC, RBX1, SREBF1, STARD4, TGFB1, TP53, USP7, ZFP161, ZNF22 | 24 | 14 | Cell cycle, gene expression, DNA replication, recombination and repair |
| AHR, CLEC11A, CYP2B6, DLG2, DLG3, DLGAP1, DNAJC11, FLNB, FOS, GRASP, GRIN1, heparin, HLTF, IL10, MAGI2, MLLT10, MMP2, MPG, NRP1, PCNX, POLR3A, POLR3F, PPARBP, RB1, RBBP9, retinoic acid, SE -MA3D, SHANK2, SMARCA4, S MAR -CB1, SPTBN1, ST6GALNAC4, TCOF1 (includes EG:6949), YY1, ZFAND5 | 25 | 15 | Organismal development, gene expression, cancer |
Selected genetic networks with High scores (>10) in WTPCIR versus KOPCIR comparison
| Molecules in network | Score | Focus genes | Top functions |
|---|---|---|---|
| ADRBK2, BTRC, CCND2, Creb, DRD1, DYRK2, FCGR2B, FLU, GRIP1, HDC, HIF1A, HIF1AN, HLTF, IL11, Jnk, Mapk, MAPT, NCAM1, NPR3, P38 MAPK, Pdgf, PI3K, Pkc(s), PMCH, PRKG1 (includes EG:5592), RUNX -1, Scf, SLC6A3, SP1, TCF12, Tgf beta, TLR4, Vegf, WNT5A,YES1 | 45 | 24 | Cell-to-cell signalling and interaction, cellular growth and proliferation, cellular development |
| Akt, Ap1, APAF1, CXCL11 (includes EG: 6373), DUSP6, FLI1, FST, Hsp90, Jnk, LDL R, Mapk, NR3C1, P38 MAPK, p70 S6k, Pdgf, PDGFC, PEPCK, PI3K, PIK3C3, PIK3CA, PMCH, PP1/PP2A, PPARGC1A, PPM1L, PPP1R11, PSCDBP, PSMC3IP, RASSF1, Scf, SULF1, TFDP1,Tgf-β, TLR3, TRAF3, VCAM1 | 40 | 22 | Endocrine system development and function, lipid metabolism, molecular transport |
| AM0TL1, β-estradiol, BMX, CD44, CDH11, CEBPG, CXCR7, DAG1, EIF2S3, FIGF, GBP2 (includes EG:14469), GFAP, GPC1, GPRC5A, IFNGR2, IL6, IL15, KDR, L-carnitine, LARGE, MVP, NFKBIZ, NRP1, PLP1, PPP5C, PRKDC, PSEN1, psychosine, RAPGEF5, SDC3, SNX10, ST6GAL1, TNF, TNFAIP8, VEGFC | 26 | 16 | Cellular movement, cardiovascular system development and function, organismal development |
| ARCN1, ATM/ATR, BCL10, BRCA1, BRCC3, BRE, CASP9, CCND2, CHEK2, DAG1, ELK1, EPOR, GAST, HDC, HMGN3, IL3, IL1RL1, KLF7, MDC1, PCDH7, PLK3, PTX3, RAD50, RANBP9, RAPGEF5, RELB, ROB01, SRPK2, TNF, TNFAIP3, TNFAIP6, TNFAIP8, TROVE2, USP11, ZFAND5 | 26 | 16 | Cell death, cell cycle, cancer |
| ATR, Caspase, CDH1, CDT1, CEP55, CUL4B, ERCC1, ETS1, FAM3C, Groucho, HAS2, HNRPA2B1, HRAS, HRASLS, IGFBP3,IGSF4(includesEG:23705), JMJD1C, MATN4, MLLT4, NOTCH1, P8, PAXIP1, PVR, PVRL- 3, RUNX1, SOAT1, SON, TIMP3, TLE1, TP53, TP53BP1, TRIM44, UPP1, UTY, Zn2+ | 24 | 15 | Cell death, connective tissue disorders, cancer |
| ATXN1, AURKA, CDC7, CEP55, CHGN, DBF4, DDX6 (includes EG:1656), EP400, GAPDH (includes EG:2597), GPS2, GSR, JMJD1C, KIAA1267, MAP4, MARK4 (includesEG:57787), MCM2, MCM4, MCM6, MCM7, MED6, MGA (includes EG:23269), MLL, PPP1R15A (includes EG:23645), PRNP, PVRL3, SFRS10, TBL1X, TFDP1, THPO, TNFRSF10A (includes EG:8797), TP53, TRIM44, TXNRD1, USP7,WDR5 | 24 | 15 | DNA Replication, Recombination and repair, cell cycle, cell death |
Fig. 7Functionally related gene network constructed from both the comparisons WTIR versus KOIR (A) and WTPCIR versus KOPCIR (B) related with cardiovascular system with the help of IPA 5.0.Nodes represent genes, with their shape representing the functional class of the gene product. All the focus genes are represented by pink and the higher intensity red colour represent lower P-value WTIR, wild-type IR; WTPCIR, preconditioned wild-type; KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.
Gene ontology analysis of the genes affected in WTIR versus KOIR comparison
| Relevant functions | P-value | No. of molecules |
|---|---|---|
| Organismal injury and abnormalities | 8.39E-4 – 4.76E-2 10 | 10 |
| Cardiovascular system development and function | 8.39E-4 – 4.47E-2 9 | 9 |
| Free radical scavenging | 7.59E-3 – 7.59E-3 1 | 1 |
| Cellular growth and proliferation | 7.59E-3 – 4.95E-2 23 | 23 |
| Haematological system development and function | 7.59E-3 – 4.95E-2 14 | 14 |
| Molecular transport | 7.59E-3 – 4.57E-2 12 | 12 |
| Cellular development | 7.59E-3 – 4.47E-2 7 | 7 |
| Connective tissue development and function | 7.59E-3 – 4.47E-2 6 | 6 |
| Drug metabolism | 7.59E-3 – 4.47E-2 6 | 6 |
| Cellular movement | 7.59E-3 – 4.47E-2 19 | 19 |
| Cell cycle | 7.59E-3 – 3.74E-2 7 | 7 |
| Nucleic acid metabolism | 7.59E-3 – 3.74E-2 2 | 2 |
| DNA replication, recombination and repair | 7.59E-3 – 3.00E-2 4 | 4 |
| Metabolic disease | 7.59E-3 – 3.00E-2 4 | 4 |
| Cardiovascular disease | 6.18E-3 – 4.47E-2 8 | 8 |
| Tissue development | 5.89E-4 – 4.90E-2 22 | 22 |
| Skeletal and muscular system development and function | 5.89E-4 – 4.47E-2 10 | 10 |
| Cell death | 4.89E-3 – 4.76E-2 11 | 11 |
| Embryonic development | 4.89E-3 – 4.47E-2 4 | 4 |
| Cell-to-cell signalling and interaction | 4.61E-3 – 4.47E-2 19 | 19 |
| Cellular assembly and organization | 3.58E-3 – 4.47E-2 21 | 21 |
| Skeletal and muscular disorders | 3.58E-3 – 4.47E-2 11 | 11 |
| Nutritional disease | 3.00E-2 – 3.74E-2 1 | 1 |
| Protein trafficking | 2.26E-2 – 3.00E-2 2 | 2 |
| Organismal development | 1.58E-3 – 4.57E-2 15 | 15 |
| Vitamin and mineral metabolism | 1.51E-2 – 4.57E-2 4 | 4 |
| Cell signalling | 1.51E-2 – 4.57E-2 19 | 19 |
| Post-translational modification | 1.51E-2 – 3.74E-2 4 | 4 |
| Cellular function and maintenance | 1.51E-2 – 2.26E-2 5 | 5 |
| Gene expression | 1.21E-3 – 4.91E-2 27 | 27 |
| Lipid metabolism | 1.17E-3 – 4.47E-2 6 | 6 |
Gene ontology analysis of the genes affected in WTPCIR versus KOPCIR comparison
| Relevant functions | P-value | No of Molecules |
|---|---|---|
| Cellular compromise | 9.02E-3 – 4.43E-2 7 | 7 |
| Lipid metabolism | 9.02E-3 – 4.43E-2 6 | 6 |
| Organismal injury and abnormalities | 9.02E-3 – 4.43E-2 6 | 6 |
| Cardiovascular disease | 9.02E-3 – 4.43E-2 4 | 4 |
| Organismal development | 9.02E-3 – 4.43E-2 4 | 4 |
| Carbohydrate metabolism | 9.02E-3 – 4.43E-2 3 | 3 |
| Endocrine system disorders | 9.02E-3 – 4.43E-2 3 | 3 |
| Small molecule biochemistry | 9.02E-3 – 4.43E-2 23 | 23 |
| Respiratory system development and function | 9.02E-3 – 4.43E-2 2 | 2 |
| Molecular transport | 9.02E-3 – 4.43E-2 12 | 12 |
| Skeletal and muscular system development and function | 9.02E-3 – 4.43E-2 11 | 11 |
| Skeletal and muscular disorders | 9.02E-3 – 4.38E-2 9 | 9 |
| Tissue development | 9.02E-3 – 4.38E-2 12 | 12 |
| Organ Development | 9.02E-3 – 3.56E-2 6 | 6 |
| DNA replication, recombination, and repair | 9.02E-3 – 3.56E-2 5 | 5 |
| Cardiovascular system development and function | 9.02E-3 – 2.68E-2 4 | 4 |
| Cell Signalling | 8.21E-3 – 4.43E-2 5 | 5 |
| Cellular assembly and organization | 7.08E-6 – 4.43E-2 17 | 17 |
| Embryonic development | 6.85E-3 – 4.43E-2 9 | 9 |
| Cell death | 6.85E-3 – 4.43E-2 8 | 8 |
| Cellular growth and proliferation | 4.49E-4 – 4.43E-2 15 | 15 |
| Cell-to-cell signalling and interaction | 4.49E-4 – 4.43E-2 13 | 13 |
| Organismal survival | 3.02E-2 – 4.11E-2 15 | 15 |
| Vitamin and mineral metabolism | 2.68E-2 – 4.43E-2 2 | 2 |
| Amino acid metabolism | 2.44E-2 – 4.43E-2 9 | 9 |
| Post-translational modification | 2.44E-2 – 4.43E-2 8 | 8 |
| Protein trafficking | 2.03E-2 – 2.03E-2 5 | 5 |
| Cellular function and maintenance | 1.80E-2 – 4.43E-2 6 | 6 |
| Tissue morphology | 1.65E-3 – 4.43E-2 16 | 16 |
| Gene expression | 1.18E-3 – 4.43E-2 10 | 10 |
Fig. 8Independent validation of down-regulated genes by real-time RT-PCR. *P < 0.05 compared with wild-type ischaemia/reperfusion group, *P < 0.05 compared with WT ischaemia/reperfusion, #P < 0.05 compared with WT preconditioning, †P < 0.05 compared with KO ischaemia/reperfusion. WTIR, wild-type IR; WTPCIR, preconditioned wild-type; KOIR, Flk-1+/− knockout IR; KOPCIR, preconditioned Flk1+/− knockout.